CLINICAL TRIALS PROFILE FOR OXAPROZIN
✉ Email this page to a colleague
All Clinical Trials for oxaprozin
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00688961 ↗ | Effects of Omacor and Aspirin on Platelet Function | Completed | Sanford Research | Early Phase 1 | 2007-06-01 | Omacor (now Lovaza) is a pharmaceutical omega-3 fatty acid product. Omega-3 fatty acids can affect blood clotting by altering the function of the blood platelets. Aspirin can do the same. The purpose of this study is to determine the individual and combined effects of these two agents on platelet function using a whole blood method. |
NCT02017197 ↗ | Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil | Completed | Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 | 2014-08-01 | The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks. |
NCT02017197 ↗ | Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil | Completed | Federal University of São Paulo | Phase 4 | 2014-08-01 | The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks. |
NCT03350386 ↗ | Drug-drug Interaction Study of FYU-981 and Oxaprozin | Completed | Fuji Yakuhin Co., Ltd. | Phase 1 | 2017-11-02 | This is an open-label, 2-period add-on study to assess the drug-drug interaction between FYU-981 and oxaprozin. The purpose of this study is to investigate the pharmacokinetics of each period in a single administration of FYU-981 and concomitant administration of FYU-981 with oxaprozin at steady -state in healthy volunteers. |
NCT03350386 ↗ | Drug-drug Interaction Study of FYU-981 and Oxaprozin | Completed | Mochida Pharmaceutical Company, Ltd. | Phase 1 | 2017-11-02 | This is an open-label, 2-period add-on study to assess the drug-drug interaction between FYU-981 and oxaprozin. The purpose of this study is to investigate the pharmacokinetics of each period in a single administration of FYU-981 and concomitant administration of FYU-981 with oxaprozin at steady -state in healthy volunteers. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for oxaprozin
Condition Name
Clinical Trial Locations for oxaprozin
Trials by Country
Clinical Trial Progress for oxaprozin
Clinical Trial Phase
Clinical Trial Sponsors for oxaprozin
Sponsor Name